StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report released on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on MRNS. Jefferies Financial Group restated a “hold” rating and set a $0.50 price objective (down from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a report on Monday, September 23rd. JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. Finally, EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. One analyst has rated the stock with a sell rating, eight have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Stock Performance

NASDAQ MRNS opened at $0.54 on Tuesday. The stock has a market cap of $29.97 million, a PE ratio of -0.22 and a beta of 1.03. The firm has a 50-day moving average of $0.38 and a 200-day moving average of $0.98. Marinus Pharmaceuticals has a 52-week low of $0.22 and a 52-week high of $10.50.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its position in Marinus Pharmaceuticals by 1,968.5% in the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 126,752 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Marinus Pharmaceuticals by 34.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after purchasing an additional 1,219,871 shares during the last quarter. World Investment Advisors LLC acquired a new position in Marinus Pharmaceuticals during the 3rd quarter worth approximately $104,000. Jacobs Levy Equity Management Inc. lifted its stake in Marinus Pharmaceuticals by 39.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock valued at $729,000 after purchasing an additional 117,255 shares during the last quarter. Finally, Suvretta Capital Management LLC boosted its position in Marinus Pharmaceuticals by 32.8% in the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after buying an additional 1,253,901 shares in the last quarter. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.